Costs and utilities used in the model
| Cost or utility | Parameter estimate (range) | Reference no. | |
|---|---|---|---|
| Costs, $ | |||
| Transplant | 121732 | (91299–152165) | (42) |
| Post-transplant care | 17 976 | (13482–22470) | (42) |
| Antiviral therapy, by algorithm | |||
| Simeprevir-based combination therapy (24-wk pegylated interferon + ribavirin) | 46157 | (34618–57696) | (13) |
| Simeprevir-based combination therapy (48-wk pegylated interferon + ribavirin) | 55811 | (41858–69764) | (13) |
| Sofosbuvir-based combination therapy (12 wk) | 55000 | (41250–68750) | (13) |
| ABT-450–based combination therapy | 50000 | (40000–62500) | Assumed |
| Pegylated interferon + ribavirin, 48 wk | 19948 | (14961–24935) | (14) |
| Pegylated interferon + ribavirin, 24 wk | 9 974 | (7481–12467) | (14) |
| Adverse event, wkly | |||
| Anemia | 107 | (80–134) | (43) |
| Depression | 73 | (55–91) | (43) |
| Pruritus | 12 | (9–15) | (43) |
| Rash | 12 | (9–15) | (43) |
| Anti-HCV test | 14.48 | (10.86–18.10) | (44) |
| HCV RNA test | 100 | (75–125) | (44) |
| Utilities | |||
| Age, mean for Canadian population, yr | |||
| 25–34 | 0.90 | (0.89–0.92) | (45), (46) |
| 35–44 | 0.88 | (0.86–0.91) | (45), (46) |
| 45–54 | 0.86 | (0.83–0.88) | (45), (46) |
| 55–64 | 0.83 | (0.80–0.87) | (45), (46) |
| Utility for health states related to chronic HCV infection | |||
| Non-cirrhosis (fibrosis stage 0–3) | 0.73 | (0.69–0.77) | (47) |
| Compensated cirrhosis (fibrosis stage 4) | 0.69 | (0.65–0.73) | (47) |
| Hepatocellular carcinoma | 0.72 | (0.68–0.75) | (47) |
| Decompensated cirrhosis* | 0.65 | (0.65–0.73) | (47), (48) |
| Post-transplant | 0.75 | (0.70–0.79) | (47) |
| Viral clearance | 0.80 | (0.76–0.84) | (47) |
| On treatment | 0.71 | (0.67–0.75) | (47) |
Note: HCV = hepatitis C virus.
↵* The study (47) did not include patients with decompensated cirrhosis, so utility for these patients was determined by adjusting the chronic HCV infection utility score according to a disutility value published in the systematic review. (48)